otamixaban

Small moleculeexperimental

Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial. — Wikipedia

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 1, 2004 (NCT00133731)

Timeline

2000s

Jan 1, 2004
Earliest Phase 2 Sponsor(trial)

2010s

Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Jan 1, 2010
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Coagulation factor XINHIBITOR
F10 inhibitor
- Coagulation factor X (F10) ↗

Chemistry & pharmacology

Loading structure…

SMILES

COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1

Mol. weight: 446.51 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaOtamixaban ↗
ChEMBLCHEMBL46618 ↗

Also known as

2-(3-carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester
2-(r)-(3-carbamimidoylbenzyl)-3-(r)-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester
fxv 673
otamixaban
otamixaban
otamixaban
otamixaban

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01126086	Phase 1	May 1, 2010	Sanofi
NCT01076764	Phase 3	Apr 1, 2010	Sanofi
NCT01120314	Phase 1	Apr 1, 2010	Sanofi
NCT00317395	Phase 2	Jun 1, 2006	Sanofi
NCT00133731	Phase 2	Sep 1, 2004	Sanofi

Showing 5 of 5 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Sanofi	For profit	5	5	3	2004

1 organizations

Page 1 / 1